Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: A meta-analysis of randomized controlled trials

International Journal of Cancer

Volumn 124, Issue 12, 2009, Pages 2982-2988

  Zhang, Chuan Hai ^a   Xu, Ge Liang ^b   Jia, Wei Dong ^b   Ge, Yong Sheng ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Ablation; Hepatocellular carcinoma; IFN ; Recurrence; Resection; Survival

Indexed keywords

ALPHA INTERFERON; PLACEBO; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CANCER STAGING; LIVER TUMOR; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RISK; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 65649140040     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24311     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Murray CJL, Lopez AD. Mortality by causes for eight regions of the world: global burden of disease study. Lancet 1997;349:1269-1276 (Pubitemid 27192468)
3. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management on hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-430 (Pubitemid 32844200)
4. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-524 (Pubitemid 34183954)
5. Clavien PA. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg 2007;245:843-845
6. Llovet JM, Fuster J, Bruix J. Intention to treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-1440
7. Makuuchi M, Donadon M, Torzilli G. Hepatic resection for hepatocellular carcinoma in cirrhosis. Ann Ital Chir 2008;79:111-115
8. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J. A randomized controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245:831-842 (Pubitemid 46809282)
9. Shiina S, Tagawa K, Niwa Y, Unuma T, Komatsu Y, Yoshiura K, Hamada E, Takahashi M, Shiratori Y, Terano A. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in146 patients. AJR Am J Roentgenol 1993;160:1023-1028 (Pubitemid 23141242)
10. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991;214:114-117
11. Pompili M, Rapaccini GL, de Luca F, Caturelli E, Astone A, Siena DA, Villani MR, Grattagliano A, Cedrone A, Gasbarrini G. Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. Cancer 1997;79:1501-1508 (Pubitemid 27154779)
12. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-1554 (Pubitemid 44970357)
13. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-207 (Pubitemid 36169630)
14. Peon RT, Fan ST, Ng TO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-507 (Pubitemid 30640096)
15. Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 1998;133:183-188 (Pubitemid 28092919)
16. Lau WY, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008;247:43-48
17. Boucher E, Corbinais S, Rolland Y, Bourguet P, Guyader D, Boudjema K, Meunier B, Raoul JL. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003;38:1237-1241 (Pubitemid 37314832)
18. Ono T, Nagasue N, Kohno H, Hayashi T, Uchida M, Yukaya H, Yamanoi A. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol 1997;24:S6-18-S16-25. (Pubitemid 27209102)
19. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046-1047 (Pubitemid 29157643)
20. Colombo M, Donato MF. Prevention of hepatocellular carcinoma. Semin Liver Dis 2005;25:155-161 (Pubitemid 40781068)
21. Dunk AA, Ikeda T, Pignatelli M, Thomas HC. Human lymphoblastoidinterferon: in vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 1986;2:419-429 (Pubitemid 16086605)
22. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J, Kojiro M. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999;29:1708-1717 (Pubitemid 29247043)
23. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL. High-dose and long-term therapy with interferon alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 2000;32:43-48 (Pubitemid 30432364)
24. Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, Liu KD, Tang ZY. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003;7:587-594 (Pubitemid 36875750)
25. Von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, Oberg K, Wiedenmann B, Höcker M, Rosewicz S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95:437-448 (Pubitemid 36432418)
26. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:119-134 (Pubitemid 34229387)
27. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-323 (Pubitemid 23319890)
28. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter, randomized, controlled trial. N Engl J Med 1989;321:1501-1506 (Pubitemid 20015540)
29. Valla DC, Degos F. Chemoprevention of hepatocellular carcinoma in hepatitis C virus related cirrhosis: first, eliminate the virus. J Hepatol 2001;34:606-609 (Pubitemid 32328520)
30. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: a randomized, controlled trial. Ann Intern Med 2001;134:963-967 (Pubitemid 32466235)
31. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418-422 (Pubitemid 34595504)
32. Shiratori Y, Shiina S, Teratani T, ImamuraM, Obi S, Sato S, Koike Y, Yoshida H, Omata M. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299-306. (Pubitemid 36205926)
33. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, Liaw YF. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376-382 (Pubitemid 38063648)
34. Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005;48:71-75 (Pubitemid 40529214)
35. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006;132:458-465 (Pubitemid 43747394)
36. Emond JC, Samstein B, Renz JF. A critical evaluation of hepatic resection in cirrhosis: optimizing patient selection and outcomes. World J Surg 2005;29:124-130 (Pubitemid 40576457)
37. Johnson P, Bruix J. Hepatocellular carcinoma and the art of prognostication. J Hepatol 2000;33:1006-1008
38. Luebke T, Aleksic M, Brunkwall J. Meta-analysis of randomized trials comparing carotid endarterectomy and endovascular treatment. Eur J Vasc Endovasc Surg 2007;34:470-479 (Pubitemid 47400232)
39. Xu X, Li J, Sheng W, Liu L. Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc Dis 2008;26:48-62.
40. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med 1987;316:450-455 (Pubitemid 17035572)
41. Bohle A, Jcham D, Bock PR. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. Int Braz J Urol 2002;28:585-586
42. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917 (Pubitemid 37518510)
43. Sun HC, Zhang W. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? [author's reply]. Ann Surg 2008;247:900.
44. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-232 (Pubitemid 30614654)
45. Damdinsuren B, Nagano H, Sakon M, Kondo M, Yamamoto T, Umeshita K, Dono K, Nakamori S, Monden M. Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 2003;10:1184-1190 (Pubitemid 40486814)
46. Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine 2006;33:121-128